1-10 of 10
Jason B. Brayer, PhDMD
Close
Sort by
Journal Articles

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Taiga Nishihori, MD, Melissa Alsina, MD, Jose Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Jongphil Kim, PhD, Michael Dumala, Joel G. Turner, PhD, Daniel M Sullivan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3314.
https://doi.org/10.1182/blood-2019-131321
Published: 2019
Journal Articles

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

David A Sallman, MD, Jason B. Brayer, PhDMD, Xavier Poire, Violaine Havelange, Ahmad Awada, MD PhD, Philippe Lewalle, Kunle Odunsi, MD, Eunice S. Wang, MD, Caroline Lonez, PhD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Nathalie Braun, Anne Flament, MD, Ine Moors, MD, Tessa Kerre
Journal: Blood
Blood (2019) 134 (Supplement_1): 3826.
https://doi.org/10.1182/blood-2019-128020
Published: 2019
Journal Articles

Composition of Immune Subpopulations Influence Multiple Myeloma Disease Progression

Rupal Ramakrishnan, Alexandra Achille, Tuan Nyugen, Ian Taylor, BS, Gabriel De Avila, BS, Raghunandanreddy Alugubelli, MS, Mark B. Meads, PhD, Ariosto Siqueira Silva, PhD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4392.
https://doi.org/10.1182/blood-2019-131966
Published: 2019
Journal Articles

Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis

Ariel F Grajales-Cruz, MD, Cristian Ivan Rodriguez Arocho, MD, Ashley Rose, MD, Jamie Shapiro, PharmD, Elizabeth Finley-Oliver, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Taiga Nishihori, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Melissa Alsina, MD, Rachid Baz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3183.
https://doi.org/10.1182/blood-2019-129021
Published: 2019
Journal Articles

Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma

Taiga Nishihori, MD, Rachid Baz, MD, Leonel Ochoa, MD, Omar Alexis Castaneda Puglianini, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhDMD, Frederick L. Locke, MD, Jongphil Kim, PhD, Jinming Song, MD PhD, Michael Dumala, Melissa Alsina, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3189.
https://doi.org/10.1182/blood-2019-131451
Published: 2019
Journal Articles

Reinforcement Learning to Optimize the Treatment of Multiple Myeloma

Kenneth H. Shain, MD PhD, Daniel Hart, Ariosto Siqueira Silva, PhD, Raghunandanreddy Alugubelli, MS, Gabriel De Avila, BS, Praneeth Reddy Sudalagunta, PhD, Alexandre Tungesvik, MD, Amit Kulkarni, PhD, Carmelo Blancuicett, PhD MD, Hongyue Dai, PhD, Taiga Nishihori, MD, Jason B. Brayer, PhDMD, Brandon Blue, MD, Melissa Alsina, MD, Rachid Baz, MD, William S. Dalton, PhDMD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5511.
https://doi.org/10.1182/blood-2019-132234
Published: 2019
Journal Articles

Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia

Jason B. Brayer, PhDMD, David A Sallman, MD, Tessa Kerre, MD, Xavier Poire, MD, Violaine Havelange, Philippe Lewalle, MD, Eunice S. Wang, MD, Dominik Selleslag, MD, Sebastien Anguille, MD, Yves Beguin, MD PhD, Enkhtsetseg Purev, MD PhD, Ahmad-Samer Al-Homsi, MD, Doreen Dekker, PhD, Eytan Breman, Panagiota A. Sotiropoulou, PhD, Sarah Snykers, PhD, Nathalie Braun, Caroline Lonez, PhD, Bikash Verma, MD DVM, Frédéric F. Lehmann, MD, Marco L. Davila, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1398.
https://doi.org/10.1182/blood-2018-99-114747
Published: 2018
Journal Articles

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

David A Sallman, MD, Tessa Kerre, MD, Xavier Poire, MD, Violaine Havelange, Philippe Lewalle, MD, Marco L. Davila, MD PhD, Eunice S. Wang, MD, Doreen Dekker, PhD, Sarah Snykers, PhD, Panagiota A. Sotiropoulou, PhD, Eytan Breman, Nathalie Braun, Caroline Lonez, PhD, Bikash Verma, MD DVM, Frédéric F. Lehmann, MD, Jason B. Brayer, PhDMD
Journal: Blood
Blood (2018) 132 (Supplement 1): 902.
https://doi.org/10.1182/blood-2018-99-111326
Published: 2018
Journal Articles

Phase I/II Study of Liposomal Doxorubicin (DOX) in Combination with Selinexor (SEL) and Dexamethasone (Dex) for Relapsed and Refractory Multiple Myeloma (RRMM)

Rachid Baz, MD, Jeffrey A Zonder, MD, Kenneth H Shain, MD PhD, Melissa Alsina, MD, Jason B. Brayer, PhDMD, Mark Melody, Joel G. Turner, PhD, Jana L Dawson, Jongphil Kim, Daniel M Sullivan, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3095.
https://doi.org/10.1182/blood.V130.Suppl_1.3095.3095
Published: 2017
Journal Articles

HDAC11 Is a Candidate Therapeutic Target in Multiple Myeloma

Jason B. Brayer, PhDMD, Allison Distler, Mark B. Meads, PhD, Eva Sahakian, PhD, John J. Powers, BS, Tuan Nguyen, Melissa Alsina, MD, Taiga Nishihori, MD, Rachid Baz, MD, Javier Pinilla-Ibarz, MD PhD, Eduardo Martin Sotomayor, MD, Ken H Shain, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1800.
https://doi.org/10.1182/blood.V130.Suppl_1.1800.1800
Published: 2017